Nov 13 (Reuters) - Synta Pharmaceuticals Corp (SNTA.O: Quote, Profile, Research) said it expects to get progress milestone payments of $40 million to $50 million in 2008 from GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research) for an experimental cancer drug.
